ES2285713T3 - Enzimoinmunoanalisis electroquimioluminiscente. - Google Patents
Enzimoinmunoanalisis electroquimioluminiscente. Download PDFInfo
- Publication number
- ES2285713T3 ES2285713T3 ES96923291T ES96923291T ES2285713T3 ES 2285713 T3 ES2285713 T3 ES 2285713T3 ES 96923291 T ES96923291 T ES 96923291T ES 96923291 T ES96923291 T ES 96923291T ES 2285713 T3 ES2285713 T3 ES 2285713T3
- Authority
- ES
- Spain
- Prior art keywords
- electrochemiluminescent
- detector
- ecl
- substrate
- enzyme
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 108090000790 Enzymes Proteins 0.000 claims abstract description 56
- 102000004190 Enzymes Human genes 0.000 claims abstract description 56
- 239000000758 substrate Substances 0.000 claims abstract description 50
- 239000012491 analyte Substances 0.000 claims abstract description 45
- 238000000034 method Methods 0.000 claims abstract description 32
- 238000005259 measurement Methods 0.000 claims abstract description 17
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical group [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 claims abstract description 14
- 102000006635 beta-lactamase Human genes 0.000 claims abstract description 4
- 108090000204 Dipeptidase 1 Proteins 0.000 claims abstract 2
- 239000000203 mixture Substances 0.000 claims description 33
- 150000001875 compounds Chemical class 0.000 claims description 19
- 238000001514 detection method Methods 0.000 claims description 13
- 229910052707 ruthenium Inorganic materials 0.000 claims description 12
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 claims description 5
- 239000003242 anti bacterial agent Substances 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 claims description 3
- 230000003115 biocidal effect Effects 0.000 claims description 3
- 229950006238 nadide Drugs 0.000 claims description 3
- 102000004316 Oxidoreductases Human genes 0.000 claims description 2
- 108090000854 Oxidoreductases Proteins 0.000 claims description 2
- 108091005804 Peptidases Proteins 0.000 claims description 2
- 239000004365 Protease Substances 0.000 claims description 2
- 239000013522 chelant Substances 0.000 claims description 2
- 229910052762 osmium Inorganic materials 0.000 claims description 2
- SYQBFIAQOQZEGI-UHFFFAOYSA-N osmium atom Chemical compound [Os] SYQBFIAQOQZEGI-UHFFFAOYSA-N 0.000 claims description 2
- YYMBJDOZVAITBP-UHFFFAOYSA-N rubrene Chemical compound C1=CC=CC=C1C(C1=C(C=2C=CC=CC=2)C2=CC=CC=C2C(C=2C=CC=CC=2)=C11)=C(C=CC=C2)C2=C1C1=CC=CC=C1 YYMBJDOZVAITBP-UHFFFAOYSA-N 0.000 claims description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 1
- 238000011984 electrochemiluminescence immunoassay Methods 0.000 abstract description 91
- 238000003018 immunoassay Methods 0.000 abstract description 27
- 230000008569 process Effects 0.000 abstract description 5
- 230000035945 sensitivity Effects 0.000 abstract description 5
- 230000003197 catalytic effect Effects 0.000 abstract description 4
- 238000007796 conventional method Methods 0.000 abstract description 2
- ROFVEXUMMXZLPA-UHFFFAOYSA-N Bipyridyl Chemical compound N1=CC=CC=C1C1=CC=CC=N1 ROFVEXUMMXZLPA-UHFFFAOYSA-N 0.000 description 68
- 230000007062 hydrolysis Effects 0.000 description 40
- 238000006460 hydrolysis reaction Methods 0.000 description 40
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 27
- 229960000723 ampicillin Drugs 0.000 description 23
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 22
- 238000004458 analytical method Methods 0.000 description 21
- NGHVIOIJCVXTGV-ALEPSDHESA-N 6-aminopenicillanic acid Chemical compound [O-]C(=O)[C@H]1C(C)(C)S[C@@H]2[C@H]([NH3+])C(=O)N21 NGHVIOIJCVXTGV-ALEPSDHESA-N 0.000 description 20
- NGHVIOIJCVXTGV-UHFFFAOYSA-N 6beta-amino-penicillanic acid Natural products OC(=O)C1C(C)(C)SC2C(N)C(=O)N21 NGHVIOIJCVXTGV-UHFFFAOYSA-N 0.000 description 20
- 239000000243 solution Substances 0.000 description 16
- 239000000047 product Substances 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 12
- 229930182555 Penicillin Natural products 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 230000001965 increasing effect Effects 0.000 description 10
- 238000004020 luminiscence type Methods 0.000 description 10
- 239000000523 sample Substances 0.000 description 10
- 238000011534 incubation Methods 0.000 description 9
- 239000002953 phosphate buffered saline Substances 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 230000008859 change Effects 0.000 description 8
- 230000007071 enzymatic hydrolysis Effects 0.000 description 8
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 8
- 239000012327 Ruthenium complex Substances 0.000 description 7
- 150000003951 lactams Chemical class 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 229940127121 immunoconjugate Drugs 0.000 description 6
- 239000011049 pearl Substances 0.000 description 6
- 150000002960 penicillins Chemical class 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 5
- -1 cephalosporin lactam Chemical class 0.000 description 5
- 238000002845 discoloration Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 229940049954 penicillin Drugs 0.000 description 5
- 239000001488 sodium phosphate Substances 0.000 description 5
- 229910000162 sodium phosphate Inorganic materials 0.000 description 5
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 5
- 241000193755 Bacillus cereus Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- WZSDNEJJUSYNSG-UHFFFAOYSA-N azocan-1-yl-(3,4,5-trimethoxyphenyl)methanone Chemical compound COC1=C(OC)C(OC)=CC(C(=O)N2CCCCCCC2)=C1 WZSDNEJJUSYNSG-UHFFFAOYSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 230000021615 conjugation Effects 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 230000005281 excited state Effects 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 238000005424 photoluminescence Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 229930186147 Cephalosporin Natural products 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 229940124587 cephalosporin Drugs 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 3
- VUFNRPJNRFOTGK-UHFFFAOYSA-M sodium;1-[4-[(2,5-dioxopyrrol-1-yl)methyl]cyclohexanecarbonyl]oxy-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].O=C1C(S(=O)(=O)[O-])CC(=O)N1OC(=O)C1CCC(CN2C(C=CC2=O)=O)CC1 VUFNRPJNRFOTGK-UHFFFAOYSA-M 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108020004256 Beta-lactamase Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 229910021607 Silver chloride Inorganic materials 0.000 description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000008033 biological extinction Effects 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 150000001780 cephalosporins Chemical class 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 238000013213 extrapolation Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000012460 protein solution Substances 0.000 description 2
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 2
- HKZLPVFGJNLROG-UHFFFAOYSA-M silver monochloride Chemical compound [Cl-].[Ag+] HKZLPVFGJNLROG-UHFFFAOYSA-M 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- CBCKQZAAMUWICA-UHFFFAOYSA-N 1,4-phenylenediamine Chemical compound NC1=CC=C(N)C=C1 CBCKQZAAMUWICA-UHFFFAOYSA-N 0.000 description 1
- BZSVVCFHMVMYCR-UHFFFAOYSA-N 2-pyridin-2-ylpyridine;ruthenium Chemical compound [Ru].N1=CC=CC=C1C1=CC=CC=N1.N1=CC=CC=C1C1=CC=CC=N1.N1=CC=CC=C1C1=CC=CC=N1 BZSVVCFHMVMYCR-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 229920000049 Carbon (fiber) Polymers 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 239000012506 Sephacryl® Substances 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- HFACYLZERDEVSX-UHFFFAOYSA-N benzidine Chemical class C1=CC(N)=CC=C1C1=CC=C(N)C=C1 HFACYLZERDEVSX-UHFFFAOYSA-N 0.000 description 1
- 239000003782 beta lactam antibiotic agent Substances 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000004917 carbon fiber Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 229960004841 cefadroxil Drugs 0.000 description 1
- NBFNMSULHIODTC-CYJZLJNKSA-N cefadroxil monohydrate Chemical compound O.C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=C(O)C=C1 NBFNMSULHIODTC-CYJZLJNKSA-N 0.000 description 1
- FUBBGQLTSCSAON-PBFPGSCMSA-N cefaloglycin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)COC(=O)C)C(O)=O)=CC=CC=C1 FUBBGQLTSCSAON-PBFPGSCMSA-N 0.000 description 1
- 229950004030 cefaloglycin Drugs 0.000 description 1
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 description 1
- 229940106164 cephalexin Drugs 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 239000012084 conversion product Substances 0.000 description 1
- 229960000956 coumarin Drugs 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 238000000840 electrochemical analysis Methods 0.000 description 1
- 230000005670 electromagnetic radiation Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 238000012543 microbiological analysis Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/535—Production of labelled immunochemicals with enzyme label or co-enzymes, co-factors, enzyme inhibitors or enzyme substrates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
- C07F15/0046—Ruthenium compounds
- C07F15/0053—Ruthenium compounds without a metal-carbon linkage
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/533—Production of labelled immunochemicals with fluorescent label
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US48476695A | 1995-06-07 | 1995-06-07 | |
| US484766 | 1995-06-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2285713T3 true ES2285713T3 (es) | 2007-11-16 |
Family
ID=23925520
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES96923291T Expired - Lifetime ES2285713T3 (es) | 1995-06-07 | 1996-06-06 | Enzimoinmunoanalisis electroquimioluminiscente. |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US6524865B1 (enExample) |
| EP (1) | EP0871887B1 (enExample) |
| JP (1) | JP3784072B2 (enExample) |
| AT (1) | ATE358276T1 (enExample) |
| AU (1) | AU718767B2 (enExample) |
| CA (1) | CA2223027A1 (enExample) |
| DE (1) | DE69637001T2 (enExample) |
| ES (1) | ES2285713T3 (enExample) |
| WO (1) | WO1996041175A1 (enExample) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5866434A (en) * | 1994-12-08 | 1999-02-02 | Meso Scale Technology | Graphitic nanotubes in luminescence assays |
| US5641623A (en) * | 1995-01-04 | 1997-06-24 | Martin; Mark T. | Electrochemiluminescence assay |
| US6319670B1 (en) | 1995-05-09 | 2001-11-20 | Meso Scale Technology Llp | Methods and apparatus for improved luminescence assays using microparticles |
| AU729118B2 (en) * | 1997-02-06 | 2001-01-25 | University Of North Carolina At Chapel Hill, The | Electrochemical probes for detection of molecular interactions and drug discovery |
| WO2001006260A1 (en) * | 1999-07-19 | 2001-01-25 | California Institute Of Technology | Detection of biomolecules by sensitizer-linked substrates |
| AU2005326758B2 (en) | 2004-06-23 | 2011-07-14 | Board Of Regents Of The University Of Texas System | Methods and compositions for the detection of biological molecules using a two particle complex |
| US7906276B2 (en) | 2004-06-30 | 2011-03-15 | Kimberly-Clark Worldwide, Inc. | Enzymatic detection techniques |
| US7521226B2 (en) | 2004-06-30 | 2009-04-21 | Kimberly-Clark Worldwide, Inc. | One-step enzymatic and amine detection technique |
| US7094528B2 (en) * | 2004-06-30 | 2006-08-22 | Kimberly-Clark Worldwide, Inc. | Magnetic enzyme detection techniques |
| MX2007004079A (es) * | 2004-10-06 | 2007-06-15 | Wellstat Biologics Corp | Detecci??n de niveles elevados de prote??na her-2/neu en celulas cancerosas circulantes y tratamiento. |
| WO2007021810A2 (en) * | 2005-08-11 | 2007-02-22 | Eksigent Technologies, Llc | Microfluidic methods and apparatuses for fluid mixing and valving |
| EP2390312A1 (en) | 2005-11-29 | 2011-11-30 | Gamida Cell Ltd. | Methods of improving stem cell homing and engraftment |
| US7820394B2 (en) | 2005-12-02 | 2010-10-26 | Catassays | Ultrasensitive bioanalytical assays based on the use of high-gain catalytic chemical amplification |
| WO2007121465A2 (en) * | 2006-04-18 | 2007-10-25 | Wellstat Biologics Corporation | Detection of proteins from circulating neoplastic cells |
| CA2684265A1 (en) * | 2007-04-19 | 2008-10-30 | Wellstat Biologics Corporation | Detection of elevated levels of her-2/neu protein from non-isolated circulating cancer cells and treatment |
| JP4887319B2 (ja) | 2008-03-17 | 2012-02-29 | 株式会社日立ハイテクノロジーズ | 自動分析装置、及び光電子増倍管を用いた分析システム |
| AU2009234422B2 (en) * | 2008-04-11 | 2014-05-08 | Board Of Regents Of The University Of Texas System | Method and apparatus for nanoparticle electrogenerated chemiluminescence amplification |
| EP2626693A3 (en) | 2008-05-08 | 2014-10-01 | Board of Regents of the University of Texas System | Luminescent nanostructured materials for use in electrogenerated chemiluminescence |
| JP5209705B2 (ja) | 2008-05-08 | 2013-06-12 | 株式会社日立ハイテクノロジーズ | 自動分析装置 |
| JP5124498B2 (ja) | 2009-01-30 | 2013-01-23 | 株式会社日立ハイテクノロジーズ | 自動分析装置 |
| EP2662385A4 (en) * | 2011-01-07 | 2015-11-11 | Chugai Pharmaceutical Co Ltd | METHOD FOR IMPROVING THE PHYSICAL PROPERTIES OF ANTIBODIES |
| WO2013053953A1 (en) * | 2011-10-14 | 2013-04-18 | Université de Liège | Method for measuring beta-lactam antibiotics |
| US9625465B2 (en) | 2012-05-15 | 2017-04-18 | Defined Diagnostics, Llc | Clinical diagnostic systems |
| US9081001B2 (en) | 2012-05-15 | 2015-07-14 | Wellstat Diagnostics, Llc | Diagnostic systems and instruments |
| US9213043B2 (en) | 2012-05-15 | 2015-12-15 | Wellstat Diagnostics, Llc | Clinical diagnostic system including instrument and cartridge |
| JP6483023B2 (ja) | 2012-12-06 | 2019-03-13 | エンリヴェックス セラピューティクス リミテッド | 治療用アポトーシス細胞調製物、その製造方法及びその使用 |
| EP3258269B1 (en) * | 2015-02-10 | 2019-06-05 | Shenzhen New Industries Biomedical Engineering Co. Ltd. | Reagent kit used for detecting lipoprotein-associated phospholipase a2, and preparation method and application for reagent kit |
| PL3338094T3 (pl) | 2015-08-20 | 2019-09-30 | F. Hoffmann-La Roche Ag | Test immunologiczny oparty na cząstkach z zastosowaniem pegylowanego swoistego względem analitu czynnika wiążącego |
| KR102437995B1 (ko) | 2016-03-07 | 2022-08-29 | 에프. 호프만-라 로슈 아게 | 항-p53 항체의 검출 |
| CN110234995A (zh) | 2017-02-02 | 2019-09-13 | 豪夫迈·罗氏有限公司 | 使用至少两种聚乙二醇化的分析物特异性结合试剂的免疫测定 |
| CN106645111A (zh) * | 2017-03-01 | 2017-05-10 | 桂林理工大学 | 一种电化学发光快速检测抗生素ZwittermicinA浓度的方法 |
| CN111936522B (zh) | 2018-04-18 | 2024-07-02 | 豪夫迈·罗氏有限公司 | 新型抗胸苷激酶抗体 |
| CN112639475A (zh) | 2018-08-31 | 2021-04-09 | 豪夫迈·罗氏有限公司 | Dlbcl的预后指数中的胸苷激酶(tk-1) |
| WO2020146497A1 (en) * | 2019-01-09 | 2020-07-16 | The Regents Of The University Of California | An electrochemiluminescence elisa for ps129-a-synuclein |
| CN109839501B (zh) * | 2019-01-30 | 2022-04-08 | 东南大学 | 一种测定循环肿瘤细胞的电致化学发光免疫传感器及其制备方法与应用 |
| KR20220024699A (ko) | 2019-07-22 | 2022-03-03 | 에프. 호프만-라 로슈 아게 | 자궁내막증의 비침습적 진단을 위한 혈액 바이오마커로서의 s100a12 |
| EP4004554A1 (en) | 2019-07-22 | 2022-06-01 | F. Hoffmann-La Roche AG | S100a9 as blood biomarker for the non-invasive diagnosis of endometriosis |
| WO2021013781A1 (en) | 2019-07-22 | 2021-01-28 | F. Hoffmann-La Roche Ag | Substance p as blood biomarker for the non-invasive diagnosis of endometriosis |
| WO2021013786A1 (en) | 2019-07-22 | 2021-01-28 | F. Hoffmann-La Roche Ag | S100a6 as blood biomarker for the non-invasive diagnosis of endometriosis |
| WO2021013784A1 (en) | 2019-07-22 | 2021-01-28 | F. Hoffmann-La Roche Ag | S100a8 as blood biomarker for the non-invasive diagnosis of endometriosis |
| KR20220100883A (ko) | 2019-11-15 | 2022-07-18 | 에프. 호프만-라 로슈 아게 | 환자 샘플의 질량분석법 측정을 위한 베타-락탐 항생제의 유도체화 |
| JP2023547505A (ja) | 2020-11-02 | 2023-11-10 | エフ． ホフマン－ラ ロシュ アーゲー | ＳＡＲＳ－ＣｏＶ－２ヌクレオカプシド抗体 |
| CN112964768A (zh) * | 2021-03-23 | 2021-06-15 | 海南微氪生物科技股份有限公司 | 一种Bst DNA聚合酶电致化学发光测定方法 |
| WO2022207628A1 (en) | 2021-03-30 | 2022-10-06 | F. Hoffmann-La Roche Ag | Scf as blood biomarker for the non-invasive diagnosis of endometriosis |
| WO2022207685A1 (en) | 2021-04-01 | 2022-10-06 | F. Hoffmann-La Roche Ag | Psp94 as blood biomarker for the non-invasive diagnosis of endometriosis |
| EP4341700A1 (en) | 2021-05-17 | 2024-03-27 | F. Hoffmann-La Roche AG | Sfrp4 as blood biomarker for the non-invasive diagnosis of adenomyosis |
| US20250042976A1 (en) | 2021-10-26 | 2025-02-06 | Roche Diagnostics Operations, Inc. | Monoclonal antibodies specific for sars-cov-2 rbd |
| WO2023131594A1 (en) | 2022-01-05 | 2023-07-13 | F. Hoffmann-La Roche Ag | Derivatization of compounds in patient samples for therapeutic drug monitoring (tdm) |
| CN119404103A (zh) | 2022-06-23 | 2025-02-07 | 豪夫迈·罗氏有限公司 | 用于诊断子宫内膜异位症及用于对子宫内膜异位症的分期进行分类的方法 |
| WO2024017983A1 (en) | 2022-07-22 | 2024-01-25 | F. Hoffmann-La Roche Ag | Meteorin-like protein (metrnl) as (blood) biomarker for the diagnosis of polycystic ovarian syndrome |
| JP2025524025A (ja) | 2022-07-22 | 2025-07-25 | エフ． ホフマン－ラ ロシュ アーゲー | 多嚢胞性卵巣症候群の診断のための（血液）バイオマーカーとしてのロイコトリエンａ４ヒドロラーゼ（ｌｔａ４ｈ） |
| CN119585618A (zh) | 2022-07-22 | 2025-03-07 | 豪夫迈·罗氏有限公司 | 成纤维细胞生长因子结合蛋白1(fgfbp1)作为（血液）生物标志物用于诊断多囊卵巢综合征 |
| WO2025017135A1 (en) | 2023-07-20 | 2025-01-23 | F. Hoffmann-La Roche Ag | Screening methods for antibody compositions |
| WO2025026908A1 (en) | 2023-07-28 | 2025-02-06 | Roche Diagnostics Gmbh | Serum epha1 as biomarker for endometriosis |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4293310A (en) * | 1980-03-14 | 1981-10-06 | University Of Pittsburgh | Photoelectrochemical immunoassay |
| US4818709A (en) * | 1983-01-21 | 1989-04-04 | Primus Frederick J | CEA-family antigens, Anti-CEA antibodies and CEA immunoassay |
| GB8305324D0 (en) | 1983-02-25 | 1983-03-30 | Unilever Plc | Microbiological test processes |
| US4470459A (en) | 1983-05-09 | 1984-09-11 | Halliburton Company | Apparatus and method for controlled temperature heating of volumes of hydrocarbonaceous materials in earth formations |
| US5310687A (en) * | 1984-10-31 | 1994-05-10 | Igen, Inc. | Luminescent metal chelate labels and means for detection |
| US5238808A (en) | 1984-10-31 | 1993-08-24 | Igen, Inc. | Luminescent metal chelate labels and means for detection |
| US5221605A (en) * | 1984-10-31 | 1993-06-22 | Igen, Inc. | Luminescent metal chelate labels and means for detection |
| US4877725A (en) * | 1985-04-01 | 1989-10-31 | New York Blood Center, Inc. | Immunoassays for antibodies which bind to the acquired immunodeficiency virus |
| KR960016340B1 (ko) * | 1986-04-30 | 1996-12-09 | 이겐 인코오포레이팃드 | 전기화학발광 분석법 |
| US5147806A (en) | 1988-04-29 | 1992-09-15 | Igen, Inc. | Method and apparatus for conducting electrochemiluminescence measurements |
| US4931223A (en) * | 1986-07-24 | 1990-06-05 | Tropix, Inc. | Methods of using chemiluminescent 1,2-dioxetanes |
| DE3856567T2 (de) * | 1987-11-04 | 2004-12-16 | Igen International, Inc. | Lumineszente Rhenium-Komplexe und Verfahren zur Herstellung |
| US5296191A (en) | 1988-11-03 | 1994-03-22 | Igen, Inc. | Method and apparatus for conducting electrochemiluminescent measurements |
| US5247243A (en) | 1988-11-03 | 1993-09-21 | Igen, Inc. | Method and apparatus for conducting electrochemiluminescent measurements |
| US5061445A (en) | 1988-11-03 | 1991-10-29 | Igen, Inc. | Apparatus for conducting measurements of electrochemiluminescent phenomena |
| US5068808A (en) | 1988-11-22 | 1991-11-26 | Reality Imaging Corporation | Imager and process |
| US4978613A (en) * | 1989-01-17 | 1990-12-18 | Abbott Laboratories | Beta-lactamase assay employing chromogenic precipitating substrates |
| US5187068A (en) * | 1989-06-09 | 1993-02-16 | Nicolae Luca | Method for determination of lipid moiety and apolipoprotein expressed epitope immunoreactivity on intact lipoprotein |
| US5264346A (en) | 1991-06-03 | 1993-11-23 | Chen Kirk C S | Colorimetric method for beta-lactamase assay and its applications |
| US6030773A (en) * | 1992-07-08 | 2000-02-29 | Agnello; Vincent | Chemiluminescent assay for DSDNA antibodies |
| US5527710A (en) * | 1994-12-02 | 1996-06-18 | Igen, Inc. | Rate measurements of biomolecular reactions using electrochemiluminescence |
| US5641623A (en) * | 1995-01-04 | 1997-06-24 | Martin; Mark T. | Electrochemiluminescence assay |
| FR2729759A1 (fr) * | 1995-01-19 | 1996-07-26 | Pasteur Sanofi Diagnostics | Procede de dosage ultrasensible de la troponine i cardiaque |
-
1996
- 1996-06-06 ES ES96923291T patent/ES2285713T3/es not_active Expired - Lifetime
- 1996-06-06 JP JP50221497A patent/JP3784072B2/ja not_active Expired - Fee Related
- 1996-06-06 AU AU63844/96A patent/AU718767B2/en not_active Ceased
- 1996-06-06 WO PCT/US1996/010119 patent/WO1996041175A1/en not_active Ceased
- 1996-06-06 CA CA002223027A patent/CA2223027A1/en not_active Abandoned
- 1996-06-06 DE DE69637001T patent/DE69637001T2/de not_active Expired - Fee Related
- 1996-06-06 EP EP96923291A patent/EP0871887B1/en not_active Expired - Lifetime
- 1996-06-06 AT AT96923291T patent/ATE358276T1/de not_active IP Right Cessation
-
1997
- 1997-09-11 US US08/928,075 patent/US6524865B1/en not_active Expired - Fee Related
-
2002
- 2002-09-04 US US10/234,874 patent/US7018802B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US7018802B2 (en) | 2006-03-28 |
| WO1996041175A1 (en) | 1996-12-19 |
| ATE358276T1 (de) | 2007-04-15 |
| EP0871887B1 (en) | 2007-03-28 |
| US6524865B1 (en) | 2003-02-25 |
| EP0871887A1 (en) | 1998-10-21 |
| US20040096918A1 (en) | 2004-05-20 |
| EP0871887A4 (en) | 2000-04-26 |
| AU718767B2 (en) | 2000-04-20 |
| JPH11507726A (ja) | 1999-07-06 |
| CA2223027A1 (en) | 1996-12-19 |
| DE69637001D1 (de) | 2007-05-10 |
| DE69637001T2 (de) | 2007-12-06 |
| JP3784072B2 (ja) | 2006-06-07 |
| AU6384496A (en) | 1996-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2285713T3 (es) | Enzimoinmunoanalisis electroquimioluminiscente. | |
| ES2622977T3 (es) | Ensayos homogéneos con fase de disolución | |
| ES2290953T3 (es) | Quelatos de lantanidos luminiscentes y procedimientos de uso. | |
| KR100444250B1 (ko) | 전기화학발광분석법 | |
| JP3997436B2 (ja) | 電気化学発光技術による化合物のモニターリング | |
| ES2203656T3 (es) | Analisis de proteccion de aductos. | |
| US6225127B1 (en) | Enzyme-based fluorescence biosensor for chemical analysis | |
| CN112433048A (zh) | 一种用于化学发光免疫法的试剂盒及其制备方法和应用 | |
| CN108391432B (zh) | 杂环化合物的生物偶联分子 | |
| US6316180B1 (en) | Electrochemiluminescent monitoring of compounds/electrochemiluminescence assays | |
| EP0617107B1 (en) | Method of making acridinium derivative luminesce and method of detecting test material therewith | |
| JP2000502989A (ja) | 改善された化学発光性１，２−ジオキセタン類 | |
| JPH04507194A (ja) | 化学発光組成物、化学発光法、及び分析的検定におけるその使用 | |
| ES2261213T3 (es) | Ensayo redox con quimioluminiscencia para cuantificar analitos en muestras biologicas. | |
| Sadik et al. | Novel fluorescent biosensor for pathogenic toxins using cyclic polypeptide conjugates | |
| EP1322670B1 (en) | Electrochemiluminescence from acridan compounds | |
| ES2226240T3 (es) | Empleo de reactivo derivatizados, en procedimientos de deteccion por quimioluminiscencia y electroquimiluminiscencia. | |
| US7186568B1 (en) | Electrochemiluminescence from acridan compounds | |
| JP2002191396A (ja) | ルシフェラーゼ発光反応の増強法 | |
| AU2002215610A1 (en) | Electrochemiluminescence from acridan compounds | |
| JP3792899B2 (ja) | 化学発光酵素免疫測定方法 | |
| JP2673957B2 (ja) | 電気化学的発光法および免疫検定法 | |
| KR100281494B1 (ko) | 아크리디늄 유도체의 발광 방법 및 이를 이용한 검사 대상 물질의 검출 방법 | |
| JPH11264822A (ja) | 免疫分析試薬及びそれを用いた免疫分析方法 | |
| Weilbaecher et al. | Surface immobilization of peptides on SiO/sub 2/nanobeads for a protease biosensor |